INVO Fertility, Inc.(IVF)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$2.6
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for IVF

11/13/2026: IVF (1-star) is currently NOT-A-BUY. Pass it for now.

INVO Fertility is a micro-cap healthcare services and medical device company specializing in assisted reproductive technologies through its proprietary INVOcell device and owned fertility clinics. Its core strengths include a differentiated, lower-cost intravaginal culture procedure and growing clinic-level revenues. The primary investment story rests on executing a buy-and-build strategy to scale clinic operations and expand product distribution. However, the company faces significant risks from ongoing net losses, high corporate overhead relative to revenue scale, and potential equity dilution. It is best suited for speculative or risk-tolerant investors who should closely monitor quarterly clinic acquisition progress and cash burn metrics.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile top-line revenue is expanding through clinic acquisitions, corporate scale is still small and unproven at a net income level.
Momentum investorStrong fit while signal remains positiveLow market capitalization and a micro-float can trigger sharp price movements upon positive clinical or financing announcements.
Value investorWeak fitOngoing net losses and negative earnings per share make traditional value metrics challenging to apply favorably.
Dividend investorWeak fitThe company does not pay dividends, prioritizing capital for growth and operational survival.
Low-risk investorWeak fitHigh share price volatility, regulatory dependencies, and liquidity needs expose investors to substantial equity risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap status and low float lead to frequent, wide swings in daily stock pricing.
Valuation riskMedium / highUncertainty surrounding future profitability makes earnings-based valuation models difficult to anchor.
Competition risk (traditional IVF and major fertility networks)HighLarger, well-funded clinic chains dominate patient volume and market awareness.
Business qualityMediumClinic-level margins are positive, but consolidated enterprise quality is weighed down by public company overhead.
Dividend incomeLow / noneNo cash distributions or dividends are paid to common stockholders.
Execution riskHighSuccess depends heavily on management's ability to integrate clinic acquisitions and control costs.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.10M USD
Price to earnings Ratio 0.01
1Y Target Price 80
Price to earnings Ratio 0.01
1Y Target Price 80
Volume (30-day avg) 32.4K shares
Beta 1.6
52 Weeks Range 1.59 - 80.00
Updated Date 11/15/2026
52 Weeks Range 1.59 - 80.00
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 511.8

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -49.02%
Avg. Invested days 10
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
IVF receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft company fundamentals, and weak price momentum.

Company Fundamentals

★★★★★
IVF has soft overall fundamentals (2 stars), with soft financial health, soft growth momentum, and soft ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-156.4%), weak cash generation (FCF margin -103.2%), moderate revenue growth (+4.7%).

Financial Health Rating

★★★★★
IVF's financial health is soft, with the relatively strongest area being soft liquidity, including working-capital and asset support (WC/assets -37.4%). Overall financial-health metrics support a 2-star score.

Growth Momentum Score

★★★★★
Revenue growth is IVF's strongest growth driver at +4.7% FY2025 versus FY2024 (moderate, 3 stars). By comparison, while earnings growth (-156.4%, negative) and free-cash-flow growth (-123.5%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 9.2% (soft) and 52.5% of outstanding shares are publicly tradable (solid). Insider ownership is only 0.47%, which materially reduces the ownership score.

Top 5 Institutional Investors

Virtu Financial LLC 1.37%
Essex, LLC 0.99%
Scientech Research LLC 0.70%
StoneX Group Inc 0.34%
Susquehanna International Group, LLP 0.25%

Unit Economics (Per $1K Revenue)

★★★★★
IVF generates approximately $370 of gross profit, $-854 of operating income, and $-1,032 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 2.74%

Quantitative Style Profile

★★★★★
IVF has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Fertility Clinic ServicesDirect patient care fees collected from diagnostic testing, consultations, IUI, and assisted reproductive procedures at company-operated medical centers.This is the primary driver of current top-line revenue growth.
INVOcell Device SegmentSales of the patented INVOcell medical device and specialized accessory kits to third-party clinics and distribution partners.Offers a scalable product-margin channel independent of physical clinic operations.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE 0.01
Forward PE -
Enterprise Value 3.70M
Price to Sales(TTM) 0.41
Enterprise Value 3.70M
Price to Sales(TTM) 0.41
Enterprise Value to Revenue 0.49
Enterprise Value to EBITDA -1.24
Shares Outstanding 1.19M
Shares Floating 625.80K
Shares Outstanding 1.19M
Shares Floating 625.80K
Percent Insiders 0.47
Percent Institutions 9.22

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.